1Department of Nursing, Borujerd Branch, Islamic Azad University, Borujerd, Iran
2Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran
American Journal of Cancer Prevention.
2017,
Vol. 5 No. 3, 44-45
DOI: 10.12691/ajcp-5-3-6
Copyright © 2017 Science and Education PublishingCite this paper: Mehrnoosh Aeinfar, Mehrdad Payandeh, Edris Sadeghi. The Efficacy of Ibrutinib in Two Patients with Chronic Lymphocytic Leukemia: A Case Report.
American Journal of Cancer Prevention. 2017; 5(3):44-45. doi: 10.12691/ajcp-5-3-6.
Correspondence to: Edris Sadeghi, Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran. Email:
sadeghi_mkn@yahoo.comAbstract
Ibrutinib known as a new development revolution in therapy of lymphoproliferative disorders like in patients with relapsed and refractory CLL. Aim of this study is efficacy of Ibrutinib in patients with CLL. First patient was 86-year-old man had a diagnosis of CLL established in January 2016. Peripheral blood smear showed 128900 WBC cells that 77 percent of it was absolute lymphocyte (99253 cells). He began receiving ibrutinib at daily dose of 140 mg by in 2016. Second patient was 58-year-old man was diagnosed with lymphoprolifirative disorder (CLL) at oncology clinic in January 2014. At diagnosis time, WBC count was 24000 and platelet count was 203000 and hemoglobin was 14.5 g/dl. Ibrutinib hold for two months and she treated with IVIG. After increased platlate count we try with a new policy consist of chlorambucil and procarbazine as a new regimen. She is stable for 9 months and we decide to decrease this combination, gradually. When in treatment of CLL you have limitation in old drug is better try a new class of target drug with low dosage, and increase to the standard dosage step by step. In this case causes drug induced thrombocytopenia.
Keywords